Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

AGM Statement

19 Aug 2021 07:00

RNS Number : 0241J
Calnex Solutions PLC
19 August 2021
 

19 August 2021

 

Calnex Solutions plc

("Calnex", the "Company" or the "Group")

 

AGM Statement

Calnex Solutions plc, an established provider of test and measurement solutions for the global telecommunications sector, is pleased to provide an update on trading ahead of its Annual General Meeting taking place at 9am today.

 

Calnex has continued to achieve strong trading and good order levels in the first quarter of FY22, in line with the Board's expectations. Of note in the first few months of the year has been a positive response to the Group's enhancements to its Lab Sync platform, Paragon-Neo, with customers placing encouraging levels of pre-orders ahead of launch later in the year. This new functionality will support testing on the very high speed 400G interface and the new PAM4 interface format. This is a key technology development which is expected to be widely adopted, as organisations upgrade their network infrastructure to cope with the increasing amount of data as a result of the increase in cloud computing and evolution to 5G. Additional recent product developments include the enhancement of our Field Sync platform with, what the Board believes is, the unique ability to test 5G Networks alongside the 3G and 4G support already available, increasing the attractiveness of the platform as telecoms operators look to maintaining their new 5G networks. Whilst cognisant of the uncertainty in the wider industry over the ongoing global semiconductor shortage, the Group has not experienced any negative impact on the ability to manufacture and ship product to date, and the Board continues to monitor the situation closely.

 

The Company was also pleased to receive a Gold standard accreditation from Investors in People, reflecting recognition of Calnex as an organisation with the very best in people management excellence.

 

The strength of trading and positive evolutionary trends affecting the telecoms sector described above provide the Board with continued confidence in Calnex's ability to deliver on its growth strategy and a positive outcome to the year in line with current market expectations.

 

For more information, please contact:

 

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

 

 

 

Cenkos Securities plc - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

 

 

Alma PR

+ 44(0) 20 3405 0213

Caroline Forde, Harriet Jackson, Joe Pederzolli

 

 

 

Overview of Calnex

 

Calnex designs, produces and markets test instrumentation and solutions for network synchronization and network emulation, enabling its customers to validate the performance of the critical infrastructure associated with telecoms networks. To date, Calnex has secured and delivered orders to over 600 customer sites in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Facebook.

 

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSFWSAAEFSEFA
Date   Source Headline
1st Jun 20267:30 amRNSDirector Dealing
29th May 20263:00 pmRNSExercise of Options and Total Voting Rights
26th May 20267:00 amRNSFinal Results
14th May 20267:00 amRNSNotice of Presentations
13th Apr 20267:00 amRNSFY26 Trading Update and Notice of Results
30th Mar 20267:00 amRNSHolding(s) in Company
26th Nov 20257:30 amRNSDirector Dealing
18th Nov 20257:00 amRNSInterim Results
6th Nov 202511:30 amRNS-RCalnex and Viavi Partnership
30th Oct 20257:00 amRNSNotice of Results and Presentations
8th Oct 20252:08 pmRNSExercise of Options and Total Voting Rights
16th Sep 20259:09 amRNSExercise of Options and Total Voting Rights
14th Aug 20254:12 pmRNSResult of AGM
14th Aug 20257:00 amRNSAGM Statement
15th Jul 20257:00 amRNSNotice of AGM and posting of Annual Report
16th Jun 20259:52 amRNSLong-Term Incentive Plan Awards
10th Jun 202511:59 amRNSDirector Dealing
20th May 20257:00 amRNSFinal Results
15th May 20257:00 amRNSNotice of Investor Presentation
8th Apr 20257:00 amRNSFY25 Trading Update and Notice of Results
14th Mar 20257:00 amRNSDirector Dealing
29th Jan 202510:48 amRNSExercise of Options
19th Nov 20247:00 amRNSInterim Results
4th Nov 20247:00 amRNSNotice of Results and Investor Presentation
8th Oct 20247:00 amRNSDirector/PDMR Dealing
2nd Oct 20244:57 pmRNSResult of General Meeting
6th Sep 20247:00 amRNSNotice of General Meeting
22nd Aug 20245:18 pmRNSResult of AGM
22nd Aug 20247:00 amRNSAGM Statement
18th Jul 20249:08 amRNSNotice of AGM
17th Jul 20242:00 pmRNSLong-Term Incentive Plan Awards
21st May 20247:00 amRNSFY24 Final Results
10th Apr 20247:00 amRNSNotice of Investor Presentation
3rd Apr 20247:00 amRNSFY24 Trading Update and Notice of Results
21st Feb 20249:28 amRNSExercise of Options
14th Feb 20241:08 pmRNSExercise of Options
12th Dec 20233:47 pmRNSPDMR Dealings
21st Nov 20237:00 amRNSInterim Results
1st Nov 202312:24 pmRNSChange of Nominated Adviser
26th Oct 20237:00 amRNSNotice of Investor Presentation
10th Oct 20233:17 pmRNSTrading Update and Notice of Results
25th Aug 20234:36 pmRNSPDMR Dealings
16th Aug 20231:22 pmRNSResult of AGM
16th Aug 20237:00 amRNSAGM Statement
11th Aug 20232:00 pmRNSLong-Term Incentive Plan Awards
17th Jul 20237:00 amRNSNotice of AGM
12th Jul 202312:05 pmRNSDirector/PDMR Dealings
12th Jun 20234:34 pmRNSPDMR Dealings
23rd May 20237:00 amRNSFY23 Final Results
11th May 20239:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.